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1. Introduction 
In the industrialized world, significant development and interventions were made since the 
HIV epidemic and they contributed to improved maternal health and low perinatal 
transmission rates. However, not all questions about this infection in pregnancy were 
answered. At times, obstetric health care providers for HIV-infected pregnant women were 
faced with certain clinical situations where there was limited available data to help direct 
treatment planning. This chapter will discuss recent data on various special considerations 
encountered in the management of HIV infection in pregnancy. 
2. Apparent lack of prenatal care and the lack of knowledge of available 
treatment to decrease perinatal transmission among HIV-infected women 
Vertical transmission of HIV infection was significantly reduced by offering HIV testing to 
pregnant women and implementing the Pediatrics AIDS Clinical Trials Group (PACTG) 
protocol 076 (Connor et al., 1994). The success of this protocol was dependent on women 
seeking prenatal care, where they were offered HIV screening and appropriate treatment for 
affected pregnancies and their newborns. However, HIV-infected women often do not 
obtain prenatal care. As a whole, 5–10% of women in the United States receive inadequate or 
no prenatal care (Kogan et al., 1998). HIV-infected women are even less likely to seek 
prenatal care. According to a study by Minkoff et al., 50% of HIV-infected women who gave 
birth at a municipal hospital in New York City did not have prenatal care (Minkoff et al., 
1990). In a survey of HIV-infected women in Philadelphia, only a third of these pregnant 
women reported adequate prenatal care and 20% had no prenatal care (Turner et al., 1996).  
Additionally, these women often failed to disclose their HIV infectious status when they 
presented for labor and delivery. Fifty percent of the women with inadequate prenatal care 
were actually aware of their HIV infection but did not choose to disclose to their caretaker 
when they presented for delivery at the Medical Center of LA in New Orleans (Centers for 
Disease Control and Prevention [CDC], 2004). This troubling data implies that many HIV-
infected women unknowingly, as a consequence of a lack of knowledge, infect their unborn 
children despite the availability of treatments to reduce vertical transmission (Dola et al., 
2010). These findings stress the importance of educating the public on the currently 
available interventions to reduce vertical transmission of HIV infection. 
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One of the barriers to decreasing perinatal transmission is that HIV-infected women do not 
obtain early prenatal care and thus exclude themselves from available interventions. Heath 
care providers must understand why HIV infected women are less likely to utilize prenatal 
services. Lancioni et al. reported that issues normally encountered in women without 
prenatal care - such as transportation, lack of child care, lack of insurance, and scheduling of 
appointments - were not found to be the reason why HIV infected women do not seek 
prenatal care. Rather, these women opted out of prenatal services because they feared the 
risk of disclosure and the anticipated anger from health care providers because they chose to 
continue their pregnancy (Lancioni et al., 1999). Eliminating the social stigma about HIV 
infection and educating health care providers about these women’s fears and concerns could 
help reduce the barriers in seeking prenatal care (Dola et al., 2010). 
3. Limitations of benefits of rapid HIV testing in labor and delivery 
In the United States, approximately 144 – 226 infants are infected annually with HIV (CDC, 
2007). Many of these infants were born of mothers who were not tested early in pregnancy 
or did not receive the appropriate prophylaxis treatment (CDC, 2007). Approximately a 
quarter of all people currently infected with HIV are not aware of their infectious status 
(Marks et al, 2006). Therefore, HIV screening during prenatal care is a necessity for the 
success of PACTG protocol 076. In addition, there is a high rate of HIV infection amongst 
women without prenatal care (Lindsay et al., 1991). Thus, those who most need it are 
excluded from the benefits of the PACTG protocol 076 and other obstetrical interventions to 
decrease perinatal transmission.  
Rapid HIV testing is now available to allow undiagnosed HIV-infected women one last vital 
opportunity to be tested for the infection and to decrease the risk of transmitting the disease 
to their newborns. By virtue of the fast availability of the rapid HIV test result, it is hoped 
that interventions can be instituted to decrease perinatal transmission. If a woman tested 
reactive on the rapid HIV test, she will be counseled appropriately and if agreed, she will be 
administered zidovudine prophylaxis during labor along with obstetrical interventions, and 
her neonate will receive prophylactic zidovudine after birth. This abbreviated regimen of 
zidovudine has been shown to be cost-effective (Stringer et al., 1999) and can decrease 
vertical transmission (Wade et al., 1998). Studies by Wade et al. show a reduction of vertical 
HIV transmission to 10% when zidovudine prophylaxis begins intrapartum compared to 
27% in those without any treatment (Wade et al., 1998). 
Rapid HIV testing is an excellent concept to allow undiagnosed HIV-infected women one 
last chance to decrease the risk of infecting their newborn, however, the benefits of rapid 
HIV tests may not be fully appreciated due to a large percentage of these women presenting 
in advanced labor, after rupture of membranes, or when they deliver shortly after arrival to 
the labor unit. Dola et al. retrospectively analyzed 350 parturients without prior prenatal 
care at their institution who presented to the labor unit with unknown HIV serostatus (Dola 
et al., 2010). These women often presented in active labor with cervical dilation of > 5 cm 
(48.6%); another 15.2% presented at complete cervical dilation of 10 centimeters, and 43% 
presented after ruptured membranes. The benefit of early detection of HIV infection via 
rapid testing may be less obvious in these women as perinatal transmission might already 
have occurred. Another 5.5% of these women even missed the benefits of rapid HIV testing 
by delivering their baby prior to their arrival to the hospital. It could be postulated that no 
benefit can be gained from a rapid HIV test result to direct effective management of these 
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patients during their labor and delivery (Dola et al., 2010). However, early oral zidovudine 
treatment for the newborn can be facilitated by early detection of the infection by rapid HIV 
testing on admission. Even so, recent studies reported conflicting data regarding the 
effectiveness of administering only zidovudine prophylaxis to neonates after delivery 
(Wade et al., 1998; Fiscus et al., 1999).  
Although results from rapid HIV testing is readily available - the median turn-around time 
is 66 minutes based on the CDC-sponsored MIRIAD Study (Bulterys et al.,2004), or 45 
minutes with the OraQuick Rapid HIV-1 Antibody Test at point-of-care hospitals (Cohen et 
al., 2003), Dola et al. reported that 22% of their study patients delivered within one hour 
after arrival to the labor and delivery unit, 31.6% within 2 hours, 38.4% within 3 hours, and 
47.2% within 4 hours. Therefore, in order for any rapid HIV test to be of use, the test result 
turnaround time, the time for counseling, and the time to availability of the zidovudine 
treatment must be constricted to within a few hours after admission (Dola et al., 2010).  
As a consequence, the full benefit of the rapid HIV tests may not be realized in patients 
who typically present without prenatal care - mostly in advanced labor and with 
rupture membranes (Dola et al., 2010). Due to the high prevalence of HIV infection in 
women without prenatal care (Lindsay et al., 1991), and until the rapid HIV testing 
results become available, obstetricians should consider these unregistered parturients as 
infected with HIV when they present for labor and delivery - refraining from certain 
common obstetrics practices (i.e. artificial rupture of membranes and the placement of 
an invasive fetal scalp electrode) to avoid inadvertly increasing the risk of perinatal 
transmission (Dola et al., 2010). 
4. HIV rescreening in late pregnancy – should all women be rescreened? 
A case report from Steele (Steele, 2010) describes three cases of infants whose mothers were 
screened negative for HIV infection in their first trimester of pregnancy. Since their mothers 
were not considered at high risk for HIV infection, they were not retested in the later stage 
of pregnancy according to the revised Centers for Disease Control and Prevention (CDC) 
guidelines (CDC, 2006; Branson et al., 2006). These mothers must have been infected with 
HIV later in their pregnancy as they were diagnosed with HIV infection shortly after 
delivery. Of these 3 infants, 2 developed an HIV infection (Steele, 2010).  
The revised CDC guidelines (Branson et al., 2006) recommended repeat testing for HIV 
infection in late pregnancy but before 36 weeks of gestation for women at high risk for 
acquiring the infection. Women requiring repeat testing would include: those with high risk 
behaviors, those living in 20 states with high incidence of HIV infection, those receiving care 
at facilities with incidence of HIV infection of at least 1 per 1,000 women screened, and those 
with signs and symptoms consistent with acute HIV infection (Branson et al., 2006). These 
guidelines were placed as beneficial interventions to reduce mother-to-child transmission 
(MTCT) of HIV could have been implemented in mothers not identified as HIV infected 
until late in pregnancy or until the onset of labor (Wade et al., 1998).  
Sansom et al, further supports the necessity of rescreening for HIV in the third trimester as it 
could prove to be cost-effective in preventing MTCT in a community with an HIV incidence 
of 1 per 1,000 person-years or higher. They argue that primary HIV infection may go 
undetected in women who continue to practice high-risk behaviors during pregnancy and in 
those with initial tests performed before HIV antibody development (Sansom et al., 2003). 
According to one study of 407 HIV-positive mothers, eight seroconversions happened after 
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a negative test result during or just before pregnancy. Three of the 8 seroconversions 
resulted in perinatal HIV transmissions (Fiscus et al., 1999).  
In an effort to further reduce perinatal transmission, Patterson et al. recommended that 
repeat HIV testing should be done in late pregnancy and again at time of labor and delivery 
along with the use of reflex RNA testing for women with negative antibody to detect acute 
HIV infection (Patterson et al, 2007).  Furthermore, Gray et al reported that the risk of 
acquisition of HIV infection increased by 2-fold in pregnancy after adjustment for behaviors 
risk factors (Gray et al., 2005). Although the evidence is inconclusive, this increased risk 
could be due to the hormonal changes in pregnancy, which could affect genital tract mucosa 
(Jacobson et al., 2000; Michael et al., 1997) or immune responses (Brahin, 2002; Beagley & 
Gockel, 2003), resulting in susceptibility to HIV infectivity.  
This above case report presented by Steele and the above arguments on cost-effectiveness of 
rescreening in late pregnancy support a recommendation for late pregnancy HIV screening - 
possibly including RNA reflex testing for those with negative antibody to the virus- of all 
women instead of only women known to have risk factors. However, a barrier to putting 
this into practice is that not all insurance companies will cover the cost of a repeat HIV 
screening in late pregnancy for all pregnant women unless the CDC revises its guidelines 
(Steele, 2010). 
5. Cesarean section in HIV-infected women – Are there any maternal or 
neonatal morbidities? 
Scheduled cesarean section prior to labor is recommended at 38 weeks gestation for women 
with a viral load above 1,000 copies/ml to further prevent vertical transmission of HIV 
infection (American College of Obstetricians and Gynecologists [ACOG], 2004). The 
combination of cesarean delivery and antiretroviral medications have been demonstrated to 
effectively reduce mother-to-child transmission of HIV disease (The International Perinatal 
HIV Group, 1999; The European Mode of Delivery Collaboration, 1999;Mofenson, 2002; 
Burdge et al., 2003; Mandelbrot et al., 1998; Kind et al., 1998). Cesarean deliveries are not 
without significant complications even for HIV-negative women (Allen et al., 2003; Makoha 
et al., 2004). Therefore, HIV-positive women could theoretically be at greater risk for post-
operative complications due to a relatively weakened immune system or immunodeficient 
status. However, there are conflicting reports from the currently available data with regard 
to post-cesarean morbidities incurred by HIV-infected women (The European Mode of 
Delivery Collaboration, 1999; Maiques-Montesinos et al., 1999; Grubert et al., 2002; 
Rodriguez et al., 2001; Marcollet et al., 2002; Watts et al., 2000). Most studies report an 
increased risk of post-operative morbidity, mostly infectious, in HIV-positive women 
compared with HIV-negative control subjects (Coll et al., 2002; Grubert el al., 1999; 
Vimercati et al., 2000). Additionally, the risk of complications is correlated with the degree 
of immunosuppression (Jamieson et al., 2007). Thus, those who most benefit from scheduled 
cesarean delivery to decrease vertical transmission would sustain the highest risk of 
complication from the procedure. 
A Cochrane review (Read & Newell; 2005) summarizes six studies (European Mode of 
Delivery Collaboration, 1999; Marcollet et al., 2002; Watts et al., 2000; Read et al., 2001; Faucher 
et al., 2001; Fior et al., 2004) which compare the complication rates in women receiving 
scheduled cesarean delivery, non-elective cesarean delivery, and vaginal delivery. Post-
operative morbidity was highest in women who underwent a non-elective cesarean delivery. 
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Vaginal delivery resulted in the lowest post-partum morbidity. Of note, most of these 
morbidities were post-operative fever, anemia, endometritis, and wound infection (Jamieson et 
al., 2007). Maternal deaths are rare, and these studies did not have adequate sample sizes to 
assess any potential differences in maternal mortality rate (Jamieson et al., 2007). 
Given that these HIV-infected women are at high risk for post-operative infectious 
morbidities, prophylactic antibiotics should be given according to ACOG guidelines for all 
women who undergo cesarean delivery (American College of Obstetricians and 
Gynecologists [ACOG], 2003). However, most of these studies were performed prior to the 
recommendation to give prophylactic antibiotics at least 30 minutes prior to cesarean 
delivery instead of after cord clamping, which has been shown to decrease the risk of post-
operative infection. It would be interesting to determine whether this newly recommended 
practice would reduce the risk of post-operative infection in these HIV-infected women. 
Current ACOG guidelines recommends scheduled cesarean delivery in HIV infected 
women, emphasizing the importance of performing the surgery prior to the onset of labor or 
rupture of membranes to reduce the risk of vertical transmission (ACOG, 2004) and that 
cesarean delivery performed after the onset of labor or after rupture of membranes is of 
unclear benefit with regard to decreasing vertical transmission. Based on the previously 
mentioned data, these cesarean deliveries after onset of labor or after rupture of membrane 
could be associated with an increase in maternal infectious morbidity (Rodriguez et al., 
2001; Marcollet et al., 2002; Read et al., 2001; Duarte et al., 2006). Therefore, when an HIV-
infected woman attempts vaginal delivery, she should be counseled for the increased risk of 
post-operative morbidity should she require an emergent cesarean delivery (Cavasin et al., 
2009). Marcollet et al. recommends that HIV-infected women with a low probability of 
having a successful vaginal delivery should consider a scheduled cesarean delivery 
(Marcollet et al., 2002).  
Overall, as the cost for treating postpartum morbidity is relatively low in comparison to the 
cost incurred by pediatric HIV infection, it appears that scheduled cesarean delivery is cost-
effective (Halpern et al., 2000; Mrus et al., 2000; Ratcliffe et al., 1998). 
ACOG recommends that scheduled cesarean delivery in the absence of medical or 
obstetrical indications should not be performed at less than 39 weeks of gestation, due to 
increased risk of neonatal respiratory morbidity (ACOG, 2001). This risk of respiratory 
morbidity for neonates born via cesarean section would closely approximate that of 
neonates born via the vaginal route at 39 weeks of gestation (Tita et al., 2009). In HIV-
infected women with viral load greater than 1,000 copies/ml, both ACOG and the U.S. 
Public Health Service recommend scheduled cesarean delivery at 38 weeks for prevention of 
vertical transmission of the HIV infection (ACOG, 2001; Public Health Service Task Force, 
2010). The gestational age of 38 weeks instead of 39 weeks was chosen as the timing for 
scheduled cesarean delivery with the intent to avoid spontaneous labor and rupture of 
membranes. Recent data reaffirmed an increased risk of neonatal morbidity even for those 
neonates born just a few days before 39 weeks of gestation (Tita et al., 2011). To address this 
valid clinical concern of a potential increase in neonatal respiratory distress syndrome in 
deliveries at 38 weeks in an effort to prevent mother-to-child transmission of HIV disease, 
Livingston et al and the IMPACT Protocol 1025 Study group (Livingston et al., 2010) 
performed a prospective cohort study. They concluded that after adjustment for gestational 
age and birth weight, the mode of delivery was not significantly associated with respiratory 
distress syndrome (p=.10), although a trend toward an increased risk for respiratory distress 
syndrome was noted among neonates delivered by cesarean section (either elective and non-
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elective) when compared to those delivered via the vaginal route. The overall rate of 
neonatal respiratory distress syndrome among those born beyond 37 weeks by all modes of 
delivery is low:  3.4% for 37 weeks, 1.0% for 38 weeks, and 1.1% at 39 weeks. Among those 
neonates born via elective cesarean delivery at 38 weeks of gestation, there were only 2 out 
of 227 neonates who had respiratory distress syndrome. This is reassuring data and it 
appears that respiratory distress syndrome at this late gestational age could be readily 
managed, although, an admission to the intensive care nursery for treatment might invoke 
significant parental distress. In the counseling of patients on scheduled cesarean section at 
38 weeks to prevent vertical transmission, one must include the small potential risk of 
neonatal respiratory distress syndrome. This small risk from iatrogenic premature delivery 
must then be balanced against the risk of less effective prevention of vertical transmission 
with the onset of labor or rupture of membranes if expectant management is continued until 
39 weeks of gestation. The results from this study are the first available data and are 
reassuring with regard to the low rate of neonatal morbidity associated with current 
guidelines recommending scheduled cesarean delivery at 38 weeks, therefore further 
research in this area is needed to provide more robust data regarding this intervention for 
decreasing vertical transmission.  
6. The challenge of prenatal diagnosis in HIV infected - women 
The current standard of care offers prenatal diagnosis to the general obstetrics population. 
In pregnancies complicated by HIV infection, there is a suspicion of a higher rate of false-
positive results when these women are screened with the maternal serum multiple marker 
test (Yudin et al., 2003). This may lead to a higher risk for HIV infected women to require 
definitive testing with genetic amniocentesis. Therefore it is important to review the current 
data on the usefulness of biochemical marker screening test in pregnant HIV-infected 
women. 
Variations in beta-hCG and AFP levels have been shown in HIV-infected pregnancies 
(Yudin et al., 2003; Einstein et al., 2004).  This may make calculating the risk for Down 
syndrome difficult and might result in further diagnostic procedures. Additionally, a 
patient’s immune status (CD4+ count) and viral load may be associated with abnormal 
screening test results (Neale et al., 2001; Gross et al., 2003). However, the mechanism for 
these alterations of the tested biochemical markers is unclear. It has been postulated to be 
due to the altered maternal immune status or the impact of highly active antiretroviral 
therapy on feto-maternal transfer of these markers, their metabolism or their excretion by 
the mother (Yudin et al., 2003).  
In contrast to the above findings, Brossard et al (Brossard et al., 2008) concluded that these 
tests were still useful in a HIV-infected population composed of 214 women for first 
trimester screening tests and 209 women for risk assessment for neural tube defects. 
Although, they also found a lower median of the MoM of beta-human chorionic 
gonadotrophin and pregnancy-associated plasma protein-A in HIV-infected women when 
compared to controls, they did not believe that such differences impacted the risk estimation 
for Down syndrome or neural tube defects (Brossard et al., 2008).  
Similarly, Le Meaux et al. studied a cohort of HIV-infected women in France and noted that 
untreated HIV-infection was associated with lower maternal alpha fetoprotein levels but 
there was no increase in false-positive rates in their double marker screening test (which 
included serum AFP and total beta-hCG levels) (Le Meaux et al., 2008). Therefore, future 
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research - with larger sample sizes - is needed to further investigate the plausible 
mechanisms for the alterations in these biochemical markers in HIV-infected women. 
If indeed HIV-infected women had a higher rate of false-positive maternal serum multiple 
marker screening test results it may warrant that they are more likely to require definitive 
diagnostic testing, which includes invasive procedures such as amniocentesis. Caution is 
required for HIV infected pregnant women who need amniocentesis because there is a 
potentially iatrogenic risk for perinatal transmission which might be related to elevated 
maternal viral load (Bucceri et al., 2001). Such invasive procedures might result in infected 
maternal blood leaking into the amniotic cavity as the needle is traversing the uterine wall 
or an anterior placenta (Giorlandino et al., 1996).  
Data regarding the safety of prenatal diagnostic procedures - in pregnancies complicated by 
HIV infection - are scant and based on a very small number of participants. Older studies 
conducted prior to the widespread use of zidovudine suggest an increased risk of infecting 
the unborn child through invasive diagnostic tests - such as amniocentesis, amnioscopies 
and other needle puncture procedures (Mandelbrot et al., 1996). With the use of zidovudine 
and HAART, the risk of perinatal transmission from invasive diagnostic tests may be greatly 
reduced (Shapiro et al., 1999; Maiques et al., 2003). Other studies with small numbers of 
study patients (ranging from 6-11 women) reported no perinatal transmission in newborns 
(Bucceri et al., 2001; Ekoukou et al., 2008; Coll et al., 2006). In total, of the data collected from 
published studies, amongst the women who underwent invasive procedures there were 28 
infected newborns from 82 women who did not receive antiretroviral treatment, 2 infected 
newborns from 24 women who received zidovudine treatment only, and no infected 
newborns from 78 women who received HAART treatment, (p = 0.0001) (Ekoukou et al., 
2008). Thus, it appears that the significant decline in the rate of perinatal transmission after 
invasive procedures performed during pregnancy could possibly reflect the beneficial 
impact of anti-retroviral therapy (Ekoukou et al., 2008). Additionally, the potential risk of 
perinatal transmission might not be as great as it was once thought to be with the 
implementation of HAART. However, we must consider that the above studies are limited 
by their small number of study participants.  
A policy to guide physicians to provide adequate counseling to HIV-infected women 
regarding the potential risks of early invasive prenatal diagnostic tests, and the optimal 
approach to such procedures is much needed. We venture to offer the following conclusions 
regarding prenatal diagnosis in HIV-infected women based on the above limited data. HIV-
infected pregnant women should be offered biochemical marker testing for prenatal 
diagnosis since it is unclear whether the variations in these marker levels are significant. If 
invasive sampling of the amniotic fluid is warranted, then careful judgment must be used to 
consider the patient’s risk factors for vertical transmission. Patient should be counseled that 
based on studies with small sample sizes, the risk of iatrogenic transmission of the HIV 
virus to the fetus is much lower than previously thought in the setting of optimal viral 
suppression and HAART. Ideally, patients undergoing invasive testing should be on 
antiretroviral therapy and have undetectable viral loads (Watts, 2002). Additionally, care 
should be taken to avoid penetrating the placenta during the procedure as this could 
theoretically increase maternal and fetal blood mixing, or directly inoculate the fetal blood 
(Giorlandino et al., 1996). Prenatal diagnosis should not be performed in women whose HIV 
serology is unknown, given the above concern of iatrogenic risk and the need for 
appropriate therapy prior to the procedure. There is a great need for continued 
investigations on which to establish future policy and protocol on this topic.  
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7. Management of PPROM in women infected with HIV 
The duration of rupture of membrane plays an important role in vertical transmission of 
HIV infection in term pregnancies. Minkoff et al. described a significantly increased rate of 
perinatal transmission of HIV infection in term women with low CD 4 count if they have 
ruptured their membranes for more than 4 hours (Minkoff et al., 1995). Other studies 
confirmed Minkoff’s work and found an increase of perinatal transmission from 14% to 25% 
in the setting of rupture of membranes for greater than 4 hours (Landesman et al., 1996). 
Furthermore, there is a significant rise in transmission – from 8% to 31% – among women 
with AIDS if delivery is postponed past 24 hours after rupture of membranes (International 
Perinatal HIV Group, 2001).  
These data reporting an increase in vertical transmission of the HIV infection after 
prolonged period of ruptured membranes pose a significant obstetrical dilemma for the 
management of women infected with HIV who had preterm premature rupture of the 
membranes (PPROM). The question is should all these HIV-infected women with PPROM 
be delivered at the time of first diagnosis with PPROM to avoid prolonged rupture of 
membranes, which potentially can lead to an increase in perinatal transmission of the 
disease?  Does current data suggest that we should commit these HIV-infected pregnancies 
with PPROM to extreme prematurity with immediate delivery to avoid the risk of perinatal 
transmission of HIV?  Available data on expectant management of PPROM in HIV infected 
women are limited. Currently available are two studies on PPROM in HIV infected women.   
The first study by Aagaard-Tillery et al. (Aagaard-Tillery et al. 2006) in 2006 evaluated the 
management and outcomes of 7 HIV pregnancies complicated by PPROM. They were 
diagnosed with PPROM, were expectantly management, and subsequently delivered between 
25 to 32 weeks gestation. The mean latency for these patients was 17.1 days with a median of 5 
days; one woman had a latency of 92 days. Two of 6 infants became infected with HIV through 
vertical transmission. The mothers of these two HIV-infected infants either did not receive 
antepartum or intrapartum antiretroviral therapy or only received treatment in the 
antepartum period with zidovudine monotherapy. Based on their results, the authors 
questioned whether expectant management is possible in the setting of PPROM in HIV-
infected women, provided that they receive prophylactic combination antiretroviral therapy.  
A second study in 2007 by Alvarez et al. (Alvarez et al., 2007) reported data on 18 cases of 
HIV infected women with PPROM at ≤ 34 weeks of gestation from a single center, 
delivering at an average gestational age of 31 weeks. The latency period before delivery 
ranged from 4 to 336 hours. Of those cases, 10 patients had been managed with antenatal 
antiretroviral therapy and did not have mother-to-child-transmission of HIV regardless of 
the duration of ruptured membranes, viral load, or maternal CD4 count. The remaining 8 
cases did not receive antenatal antiretroviral therapy and received only intrapartum 
nevirapine. Two of these eight neonates sustained perinatal transmission of HIV; their 
mothers did not have prenatal care and did not receive antenatal antiretroviral therapy. In 
this study, the perinatal transmission rate for HIV was 11.1% (2/18).  
Although these two studies show encouraging outcomes and are very thought provoking, 
safety of expectant management of PPROM could not be ascertained based on the small 
number of study participants. From the above data, we concluded that for HIV-infected 
women with PPROM at a very young gestational age who has suppressed viral load and on 
antenatal HAART, expectant management to allow in-utero lung maturation might be 
considered. However, as risk of morbidity from preterm birth is decreased at tertiary care 
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center beyond 30-32 weeks, there might be more advantageous for expedite delivery. The 
benefits of expectant management are still uncertain in patients not receiving antiretroviral 
treatment. Future studies on HIV infected women with PPROM prior to 34 weeks gestation 
are necessary to arrive at the optimal care plan. 
8. Could viral load in genital tract secretions have a role in perinatal 
transmission?  
Maternal viral load was determined to be the most important risk factor in perinatal 
transmission of HIV infection (The European Collaborative Study, 1999). Efforts in reduction 
of MTCT of HIV involve optimal suppression of viral load with the implementation of 
HAART. However, perinatal transmission was reported among women with undetectable 
maternal serum viral load (Cao et al., 1997; Sperling et al., 1996). Provocative data was 
gathered by the European Collaborative study. The investigators reported a 2% risk of 
vertical transmission among women with low viral load who delivered after 37 weeks by 
elective cesarean section and 11% among those delivered via the vaginal route (The 
European Collaborative Study, 1999). This might imply that other factors play an important 
role in the perinatal transmission besides maternal serum viral load. One explanation for the 
perinatal transmission in the setting of low plasma viral load and the protective effect from 
cesarean section could be that viral shedding in the female genital tract could have a role in 
perinatal transmission and that there might be a discordance between HIV-1 RNA levels in 
blood and cervicovaginal secretions (Garcia-Bujalance et al., 2004). HIV-1 RNA has been 
detected from the female cervicovaginal tract (Cu Uvin & Caliendoa, 1997) and treatment 
with HAART can suppress HIV-1 RNA to below detectable levels in both the genital tract 
and plasma of non-pregnant women (Cu Uvin et al., 2000).  
Several studies noted a strong correlation between the level of HIV-1 viral load in the genital 
tract and the plasma (Hart et al., 1999; Kovacs et al., 1999). However, in non-pregnant 
women with undetectable plasma viral load, HIV-1 RNA load can be found in their genital 
tract (Debiaggi et al., 2001). Conversely, some studies reported no correlation between the 
viral load in the plasma and genital shedding of non-pregnant women (Rasheed et al., 1996). 
One study from Kovacs et al. (Kovacs et al., 2001) reports that although there was a positive 
correlation between RNA concentrations in the plasma and the genital tract, 4% (9 of 252 
women) of their population had higher RNA concentrations in the genital secretions and 
two women had at least 10-fold higher RNA levels in genital tract secretions than in plasma. 
Different genotypic variants of HIV-1 were found in the blood and cervicovaginal lavage 
according to another study (Shaheen et al., 1999).  Garcia-Bujalance et al. reported 2 cases in 
38 HIV-1 infected pregnant women with a low plasma viral load of <50 copies/mL but with 
detectable viral load in their vaginal secretions (Garcia-Bujalance et al., 2004).  
Another factor in reducing MTCT of HIV infection can perhaps be determined by viral 
shedding in the female genital tract. The lack of correlation between the viral load in blood 
plasma and genital tract secretions might suggest that there is still risk for perinatal 
transmission in women with undetectable viral load in the plasma (Iribarren et al., 2001). 
More studies are needed to investigate on the roles of genital tract viral shedding in 
perinatal transmission and the possible benefit of using both plasma and cervicovaginal 
secretion viral loads despite undetectable viral plasma load in choosing the vaginal route of 
delivery. 
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9. Should assisted reproductive technology be available for HIV-infected men 
and women? 
Currently, about 80% of women infected with HIV are of reproductive age (CDC, 2001). 
With the current advent and widespread use of HAART in industrialized countries, HIV 
infection has become a chronic disease and those who are affected with the disease can now 
live longer and with a better quality of life (Kambin & Batzer, 2004). Furthermore, with 
current interventions, the risk of MTCT of HIV infection is now significantly declined to 
approximately 2% (The Ethics Committee of the American Society for Reproductive 
Medicine [ASRM], 2010). As a result, HIV-infected men and women may elect to have 
children. However, for discordant couple, reproduction may result in the risk of horizontal 
transmission to the uninfected partner. 
The Ethics Committee of the American Society for Reproductive Medicine (ASRM) 
established guidelines in 1994 for patients infected with HIV who might request or require 
assisted reproductive technologies (Ethics Committee of the American Fertility Society, 
1994). The committee made the following recommendations due to their concern about 
potential horizontal transmission to the uninfected partner and vertical transmission to the 
couple’s child and the potential problem to the offspring as the infected parent might 
succumb to the disease. Their recommendations are as follows: couples seeking support are 
encouraged to test for HIV infection, development of written policies on infertility treatment 
for HIV-infected people by each institution, counseling of consequences of using infected 
sperm, and advising couples on the alternative options of donor sperm, adoption, or not 
having children (Ethics Committee of the American Fertility Society, 1994).  
Since then, better understanding of the disease has been achieved, and the beneficial 
impact of HAART significantly improved survival and quality of life for HIV-infected 
persons, along with improved technique to provide virus-free sperm for reproductive 
assistance. Thus, in 2006, ASRM published its revision of the original guidelines. Obstetric 
health care providers should be aware of these revisions so that they can appropriately 
counsel their patients. 
Approximately 1 in 500 – 1,000 episodes of unprotected intercourse is estimated to result in 
horizontal transmission of the HIV infection to an uninfected partner (Mandelbrot et al., 
1997). Therefore, in discordant couples where the woman is infected with HIV and her 
partner is negative, ASRM discussed the use of homologous insemination with the 
uninfected male partner’s sperm to achieve pregnancy and to avoid the risk of transmission 
(ASRM, 2010). 
In discordant couples (with the male partner being infected), intercourse without condom 
use at the time of ovulation to attempt conception could reduce but does not eliminate the 
risk of infecting the partner. According to one study, the reported seroconversion rate was 
4.3% for couples that employed timed intercourse to attempt conception (Sauer et al., 2009). 
Couples should be counseled against this unsafe method as they could still infect their 
partner.  For these instances of male-infected sero-discordant couples, specific methods for 
sperm preparation and testing (density gradient and swim-up technique to obtain sperm 
and PCR virus detection assay) have been described (Kambin et al., 2004; Sauer et al., 2009; 
Semprini et al., 1998). The final sperm sample was used only if it tested negative on these 
assays (Semprini et al., 1998). These techniques resulted in less than 1% of the samples 
testing positive for the virus and thus was discarded (Semprini et al., 1998). These 
techniques can markedly reduce the chance of HIV transmission to the female partner and 
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child. Specifically, Semprini et al. reported data on almost 1,600 inseminations of 513 HIV-
uninfected women in which there were 228 pregnancies. At a follow-up rate of 97.5% at 3 
months, and 92% at one year, all mothers and children were uninfected (Semprini et al., 
1998). Similarly, there was no report of transmitted HIV infection to the mother or child with 
intrauterine insemination (Kambin et al., 2004) or intracytoplasmic sperm injection (Sauer et 
al., 2009) technique. For these male-positive discordant couples, extensive counseling should 
be performed regarding transmission risk-reduction techniques (ASRM, 2000). Health care 
providers should not overlook HIV-infected men and women’s desire to have children.  
They should make every effort to encourage these men and women to obtain care at the 
institutions with most effective methods to provide appropriate treatment and to reduce the 
chance of infecting their partner and child. 
10. Conclusion 
Significant progress was made in understanding HIV virology and important interventions 
were developed to reduce mother-to-child-transmission of this disease since the epidemic of 
this disease. Most obstetricians caring for HIV-infected women are familiar with these 
commonly employed interventions. However, there are still many difficult clinical situations 
where only scant data is available to direct management, in part due to the fortunately low 
prevalence of the disease in industrialized countries. We hope readers of this chapter would 
continue to report their challenging clinical encounters and thus, would contribute to the 
better care of these pregnant HIV-infected women. The review of these special 
considerations, hopefully, will aid obstetricians in their plan of care, raise valid questions, 
and suggest areas of future research directions. 
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